Analysts Set Align Technology, Inc. (NASDAQ:ALGN) Price Target at $182.67

Align Technology, Inc. (NASDAQ:ALGN) has been assigned a consensus rating of “Hold” from the sixteen brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $173.0909.

A number of analysts have commented on ALGN shares. Mizuho decreased their target price on Align Technology from $210.00 to $170.00 and set an “outperform” rating on the stock in a research report on Monday, October 13th. Morgan Stanley decreased their target price on Align Technology from $154.00 to $142.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Jefferies Financial Group reiterated a “hold” rating and set a $140.00 target price (down from $215.00) on shares of Align Technology in a research report on Friday, October 10th. Zacks Research upgraded Align Technology from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 30th. Finally, UBS Group decreased their target price on Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Thursday, October 16th.

Align Technology Price Performance

Shares of ALGN stock opened at $136.00 on Tuesday. The business’s fifty day moving average price is $134.29 and its 200 day moving average price is $162.73. Align Technology has a 1-year low of $122.00 and a 1-year high of $246.19. The firm has a market capitalization of $9.86 billion, a PE ratio of 22.93, a P/E/G ratio of 1.54 and a beta of 1.70.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the company earned $2.41 EPS. The company’s revenue was down 1.6% on a year-over-year basis. Align Technology has set its Q3 2025 guidance at EPS. Equities research analysts expect that Align Technology will post 7.98 earnings per share for the current fiscal year.

Align Technology announced that its board has approved a share buyback program on Tuesday, August 5th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, CEO Joseph M. Hogan acquired 7,576 shares of Align Technology stock in a transaction dated Friday, August 1st. The shares were acquired at an average cost of $131.49 per share, for a total transaction of $996,168.24. Following the completion of the transaction, the chief executive officer directly owned 184,945 shares of the company’s stock, valued at $24,318,418.05. The trade was a 4.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.66% of the company’s stock.

Institutional Trading of Align Technology

A number of large investors have recently made changes to their positions in ALGN. Norges Bank acquired a new stake in shares of Align Technology during the second quarter valued at $155,297,000. Ninety One UK Ltd boosted its stake in shares of Align Technology by 58.7% during the first quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock valued at $307,800,000 after acquiring an additional 716,954 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of Align Technology by 510.3% during the first quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider’s stock valued at $112,396,000 after acquiring an additional 591,588 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of Align Technology by 4,217.3% during the first quarter. Mackenzie Financial Corp now owns 426,205 shares of the medical equipment provider’s stock valued at $67,707,000 after acquiring an additional 416,333 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Align Technology by 94.5% during the second quarter. Nordea Investment Management AB now owns 638,341 shares of the medical equipment provider’s stock valued at $121,055,000 after acquiring an additional 310,091 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.